))
Revisiting Seamless 2/3 Trial for GLP-1 Agonist
Manage episode 479615905 series 3646318
Content provided by Berry. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Berry or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
In this episode of "In the Interim..." we revisit the ground-breaking seamless phase 2/3 clinical trial for the GLP-1 agonist, dulaglutide—better known as Trulicity. We discuss the intricacies of the adaptive trial design, and the unique features that helped expedite development by 12-18 months. Listeners will gain insight into how Bayesian algorithms and innovative statistical methods were pivotal in navigating a complex trial design, benefiting Eli Lilly's pipeline and changing the landscape of diabetes treatment.
Key Highlights:
- Outline of the trial design and the barriers faced during its inception in 2007-2008.
- Explanation of the Clinical Utility Index and its role in adaptive randomization.
- The DSMB's role and interaction with Bayesian decision-making models.
- Simulation-based design to optimize development efficiencies.
- Insights into the predictive power of the trial on weight loss outcomes in subsequent trials.
Quotes:
- "The trial was run entirely by Bayesian algorithms." – Scott Berry
- "They believed this utility function was absolutely the right way to go forward." – Scott Berry
10 episodes
Share
